Lumonus, a Sydney-based company specializing in radiation oncology workflow solutions, has raised AUD $25 million, or approximately $16.2 million USD, in a Series B funding round led by Aviron Investment Management, with participation from Oncology Ventures.
According to a company blog post, the new funding will fuel the expansion of Lumonus’s U.S. go-to-market and clinical success teams, while also driving further development of its flagship products, Lumonus AI Physician and Lumonus AI Dosimetry.
Lumonus said the investment underscores growing adoption of its platform as a whole, which supports clinicians in consulting and prescribing over 280,000 cancer treatments and has already automated tens of thousands of cancer treatment plans.
“Oncology is at an inflection point. Scientific innovation in cancer treatment has advanced significantly, but the systems that support teams delivering the care have not kept pace. By combining AI-native architecture, a comprehensive end-to-end workflow approach and a commitment to partnering with care teams to solve real-world pain points, we are reimagining oncology workflows. This investment allows us to expand our world-class team and support more health systems that are ready to embrace a better way,” Keith Hansen, CEO of Lumonus, said in a statement.
